Statistics about Oral cancer

Prevalence and incidence statistics for Oral cancer:

see also prevalence and incidence page for Oral cancer

Incidence (annual) of Oral cancer: 28,900 annual cases (SEER 2002 estimate)

Incidence Rate: approx 1 in 9,411 or 0.01% or 28,900 people in USA [about data]

Incidence extrapolations for USA for Oral cancer: 28,900 per year, 2,408 per month, 555 per week, 79 per day, 3 per hour, 0 per minute, 0 per second.

Incidence statistics about Oral cancer:

The following statistics relate to the incidence of Oral cancer:

• 28,260 new cases for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 18,550 new male cases for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 9,710 new female cases for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 2,100 new cases of oral cancer in men in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 1,050 new cases of oral cancer in women in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 12 per 100,000 new cases of oral cancer in men in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 5 per 100,000 new cases of oral cancer in women in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 8,250 new cases for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 6,330 new male cases for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,920 new female cases for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 10,080 new cases for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 5,410 new male cases for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 4,670 new female cases for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 7,320 new cases for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 4,860 new male cases for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 2,460 new female cases for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)

Deaths from Oral cancer: 7,486 deaths reported in USA 1999 for cancers of lip, oral cavity or pharynx (NVSR Sep 2001)

Death rate extrapolations for USA for Oral cancer: 7,485 per year, 623 per month, 143 per week, 20 per day, 0 per hour, 0 per minute, 0 per second.

Death statistics for Oral cancer:

The following are statistics from various sources about deaths and Oral cancer:

• 7,230 estimated deaths for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 4,830 estimated male deaths for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 2,400 estimated female deaths for oral cavity/pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 690 deaths in men from oral cancer in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 340 deaths in women from oral cancer in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 4 per 100,000 deaths in men from oral cancer in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 2 per 100,000 deaths in women from oral cancer in Canada 2004 (Canadian Cancer Statistics, National Cancer Institute of Canada, 2004)
• 2,070 estimated deaths for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,460 estimated male deaths for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 610 estimated female deaths for pharynx cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,890 estimated deaths for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,070 estimated male deaths for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 820 estimated female deaths for mouth cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,700 estimated deaths for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 1,100 estimated male deaths for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• 600 estimated female deaths for tongue cancer in the US 2004 (Cancer Facts and Figures, American Cancer Society, 2004)
• Mortality rates for oral cavity cancer deaths in various countries:
  • 1.8 men per 100,000 population in the US 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in the US 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.2 men per 100,000 population in Australia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.92 women per 100,000 population in Australia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.7 men per 100,000 population in Austria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Austria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.3 men per 100,000 population in Azerbaijan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.5 women per 100,000 population in Azerbaijan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.9 men per 100,000 population in Bulgaria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.5 women per 100,000 population in Bulgaria 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.3 men per 100,000 population in Canada 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Canada 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.1 men per 100,000 population in Chile 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.4 women per 100,000 population in Chile 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.2 men per 100,000 population in China 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.0 women per 100,000 population in China 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.4 men per 100,000 population in Colombia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.0 women per 100,000 population in Colombia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 7.2 men per 100,000 population in Croatia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Croatia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 4.0 men per 100,000 population in Cuba 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.6 women per 100,000 population in Cuba 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 4.4 men per 100,000 population in Czech Republic 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Czech Republic 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.0 men per 100,000 population in Denmark 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.2 women per 100,000 population in Denmark 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 5.3 men per 100,000 population in Estonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.0 women per 100,000 population in Estonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.7 men per 100,000 population in Finland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in Finland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 4.4 men per 100,000 population in France 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in France 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.2 men per 100,000 population in Germany 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Germany 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.5 men per 100,000 population in Greece 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.5 women per 100,000 population in Greece 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 10.9 men per 100,000 population in Hungary 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.6 women per 100,000 population in Hungary 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.4 men per 100,000 population in Ireland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Ireland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.3 men per 100,000 population in Israel 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Israel 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.0 men per 100,000 population in Japan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Japan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.5 men per 100,000 population in Kazakhstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.2 women per 100,000 population in Kazakhstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.1 men per 100,000 population in Kyrgyzstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population per 100,000 population in Kyrgyzstan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 4.8 men per 100,000 population in Latvia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000196.7 American Cancer Society)
  • 0.7 women per 100,000 population in Latvia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 5.0 men per 100,000 population in Lithuania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Lithuania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.1 men per 100,000 population in Macedonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Macedonia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.2 men per 100,000 population in Mauritius 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Mauritius 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.4 men per 100,000 population in Mexico 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Mexico 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.5 men per 100,000 population in the Netherlands 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in the Netherlands 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.3 men per 100,000 population in New Zealand 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in New Zealand 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.4 men per 100,000 population in Norway 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in Norway 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.7 men per 100,000 population in Poland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Poland 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.9 men per 100,000 population in Portugal 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.6 women per 100,000 population in Portugal 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 6.7 men per 100,000 population in Republic of Moldova 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Republic of Moldova 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 4.2 men per 100,000 population in Romania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in Romania 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 5.3 men per 100,000 population in the Russian Federation 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in the Russian Federation 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 9.5 men per 100,000 population in Slovakia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.0 women per 100,000 population in Slovakia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.4 men per 100,000 population in Slovenia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Slovenia 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 3.9 men per 100,000 population in Spain 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in Spain 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.3 men per 100,000 population in Sweden 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.7 women per 100,000 population in Sweden 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.5 men per 100,000 population in Trinidad and Tobago 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.1 women per 100,000 population in Trinidad and Tobago 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 2.2 men per 100,000 population in Turkmenistan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in Turkmenistan 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.8 men per 100,000 population in the UK 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.8 women per 100,000 population in the UK 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 1.3 men per 100,000 population in Venezuela 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)
  • 0.9 women per 100,000 population in Venezuela 2000 (Cancer Incidence, Mortality, and Prevalence Worldwide, GLOBOCAN, 2000 American Cancer Society)

Survival rate statistics for Oral cancer:

The following are statistics from various sources about the survival rate for Oral cancer:

• 60% of white people survive 5 years for oral cavity cancer in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
• 36% of African American people survive 5 years for oral cavity cancer in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
• 57% survive 5 years for oral cavity cancer in the US 1992-99 (Cancer Facts and Figures, American Cancer Society, 2004)
• 52.3% of people with oral cavity and pharynx cancer survive after 5 years in the US 1983-90 (SEER)
• 5-year survival rate for black people with oral cavity and pharynx cancer is 33.6% in the US 1983-90 (SEER)
• 5-year survival rate for people with oral cavity and pharynx cancer is 52.3% in the US 1983-90 (SEER)
• 5-year survival rate for white people with oral cavity and pharynx cancer is 54.6% in the US 1983-90 (SEER)

Average life years lost for Oral cancer: 16.7 years for oral cavity/pharynx cancers (SEER)¹

Society statistics for Oral cancer

Hospitalization statistics for Oral cancer:

The following are statistics from various sources about hospitalizations and Oral cancer:

• 0.1% (12,649) of hospital episodes were for malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 89% of hospital consultations for malignant neoplasm of lip, oral cavity and pharynx required hospital admission malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 67% of hospital episodes for malignant neoplasm of lip, oral cavity and pharynx were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 33% of hospital episodes for malignant neoplasm of lip, oral cavity and pharynx were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 16% of hospital admissions for malignant neoplasm of lip, oral cavity and pharynx required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 9.3 days was the mean length of stay in hospitals for malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 4 days was the median length of stay in hospitals for malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 60 was the mean age of patients hospitalised for malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 49% of hospitalisations for malignant neoplasm of lip, oral cavity and pharynx occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 16% of hospitalisations for malignant neoplasm of lip, oral cavity and pharynx occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 16% of hospitalisations for malignant neoplasm of lip, oral cavity and pharynx were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.16% (84,442) of hospital bed days were for malignant neoplasm of lip, oral cavity and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.003% (387) of hospital consultant episodes were for malignant neoplasm of lip in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 97% of hospital consultant episodes for malignant neoplasm of lip required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 59% of hospital consultant episodes for malignant neoplasm of lip were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 41% of hospital consultant episodes for malignant neoplasm of lip were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 5% of hospital consultant episodes for malignant neoplasm of lip required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 5.4 days was the mean length of stay in hospitals for malignant neoplasm of lip in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 2 days was the median length of stay in hospitals for malignant neoplasm of lip in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 70 was the mean age of patients hospitalised for malignant neoplasm of lip in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 20% of hospital consultant episodes for malignant neoplasm of lip occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 42% of hospital consultant episodes for malignant neoplasm of lip occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 49% of hospital consultant episodes for malignant neoplasm of lip were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.002% (1,096) of hospital bed days were for malignant neoplasm of lip in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.0026% (325) of hospital consultant episodes were for malignant neoplasm of gum in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 86% of hospital consultant episodes for malignant neoplasm of gum required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 50% of hospital consultant episodes for malignant neoplasm of gum were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 50% of hospital consultant episodes for malignant neoplasm of gum were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 18% of hospital consultant episodes for malignant neoplasm of gum required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 12.1 days was the mean length of stay in hospitals for malignant neoplasm of gum in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 5 days was the median length of stay in hospitals for malignant neoplasm of gum in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 67 was the mean age of patients hospitalised for malignant neoplasm of gum in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 29% of hospital consultant episodes for malignant neoplasm of gum occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 40% of hospital consultant episodes for malignant neoplasm of gum occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 10% of hospital consultant episodes for malignant neoplasm of gum were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.006% (2,872) of hospital bed days were for malignant neoplasm of gum in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.007% (905) of hospital consultant episodes were for malignant neoplasm of floor of mouth in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 86% of hospital consultant episodes for required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 68% of hospital consultant episodes for malignant neoplasm of floor of mouth were men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 32% of hospital consultant episodes for malignant neoplasm of floor of mouth were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 14% of hospital consultant episodes for required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 11.9 days was the mean length of stay in hospitals for malignant neoplasm of floor of mouth in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 6 days was the median length of stay in hospitals for malignant neoplasm of floor of mouth in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 61 was the mean age of patients hospitalised for malignant neoplasm of floor of mouth in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 54% of hospital consultant episodes for malignant neoplasm of floor of mouth occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 15% of hospital consultant episodes for malignant neoplasm of floor of mouth occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 14% of hospital consultant episodes for malignant neoplasm of floor of mouth were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.014% (7,510) of hospital bed days were for malignant neoplasm of floor of mouth in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.005% (612) of hospital consultant episodes were for malignant neoplasm of palate in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 90% of hospital consultant episodes for malignant neoplasm of palate required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 60% of hospital consultant episodes for malignant neoplasm of palate were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 40% of hospital consultant episodes for malignant neoplasm of palate were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 17% of hospital consultant episodes for malignant neoplasm of palate required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 8.7 days was the mean length of stay in hospitals for malignant neoplasm of palate in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 3 days was the median length of stay in hospitals for malignant neoplasm of palate in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 62 was the mean age of patients hospitalised for malignant neoplasm of palate in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 38% of hospital consultant episodes for malignant neoplasm of palate occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 19% of hospital consultant episodes for malignant neoplasm of palate occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 16% of hospital consultant episodes for malignant neoplasm of palate were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.007% (3,873) of hospital bed days were for malignant neoplasm of palate in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.005% (643) of hospital consultant episodes were for malignant neoplasm of parotid gland in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 92% of hospital consultant episodes for malignant neoplasm of parotid gland required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 60% of hospital consultant episodes for malignant neoplasm of parotid gland were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 40% of hospital consultant episodes for malignant neoplasm of parotid gland were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 13% of hospital consultant episodes for malignant neoplasm of parotid gland required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 6.7 days was the mean length of stay in hospitals for malignant neoplasm of parotid gland in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 4 days was the median length of stay in hospitals for malignant neoplasm of parotid gland in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 61 was the mean age of patients hospitalised for malignant neoplasm of parotid gland in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 39% of hospital consultant episodes for malignant neoplasm of parotid gland occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 23% of hospital consultant episodes for malignant neoplasm of parotid gland occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 11% of hospital consultant episodes for malignant neoplasm of parotid gland were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.007% (3,552) of hospital bed days were for malignant neoplasm of parotid gland in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.002% (265) of hospital consultant episodes were for malignant neoplasm of major salivary gland other than parotid in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 95% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 56% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 44% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 8% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 5.1 days was the mean length of stay in hospitals for malignant neoplasm of major salivary gland other than parotid in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 2 days was the median length of stay in hospitals for malignant neoplasm of major salivary gland other than parotid in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 56 was the mean age of patients hospitalised for malignant neoplasm of major salivary gland other than parotid in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 55% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 12% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 14% of hospital consultant episodes for malignant neoplasm of major salivary gland other than parotid were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.002% (1,096) of hospital bed days were for malignant neoplasm of major salivary gland other than parotid in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.013% (1,593) of hospital consultant episodes were for malignant neoplasm of tonsil in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 92% of hospital consultant episodes for malignant neoplasm of tonsil required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 75% of hospital consultant episodes for malignant neoplasm of tonsil were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 25% of hospital consultant episodes for malignant neoplasm of tonsil were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 16% of hospital consultant episodes for malignant neoplasm of tonsil required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 7.8 days was the mean length of stay in hospitals for malignant neoplasm of tonsil in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 4 days was the median length of stay in hospitals for malignant neoplasm of tonsil in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 58 was the mean age of patients hospitalised for malignant neoplasm of tonsil in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 60% of hospital consultant episodes for malignant neoplasm of tonsil occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 7% of hospital consultant episodes for malignant neoplasm of tonsil occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 18% of hospital consultant episodes for malignant neoplasm of tonsil were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.017% (9,102) of hospital bed days were for malignant neoplasm of tonsil in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.018% (2,348) of hospital consultant episodes were for benign neoplasm of mouth and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 100% of hospital consultant episodes for benign neoplasm of mouth and pharynx required hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 49% of hospital consultant episodes for benign neoplasm of mouth and pharynx were for men in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 51% of hospital consultant episodes for benign neoplasm of mouth and pharynx were for women in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 3% of hospital consultant episodes for benign neoplasm of mouth and pharynx required emergency hospital admission in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 1.6 days was the mean length of stay in hospitals for benign neoplasm of mouth and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 1 days was the median length of stay in hospitals for benign neoplasm of mouth and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 47 was the mean age of patients hospitalised for benign neoplasm of mouth and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 66% of hospital consultant episodes for benign neoplasm of mouth and pharynx occurred in 15-59 year olds in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 7% of hospital consultant episodes for benign neoplasm of mouth and pharynx occurred in people over 75 in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 71% of hospital consultant episodes for benign neoplasm of mouth and pharynx were single day episodes in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)
• 0.002% (1,090) of hospital bed days were for benign neoplasm of mouth and pharynx in England 2002-03 (Hospital Episode Statistics, Department of Health, England, 2002-03)

About statistics:

This page presents a variety of statistics about Oral cancer. The term 'prevalence' of Oral cancer usually refers to the estimated population of people who are managing Oral cancer at any given time. The term 'incidence' of Oral cancer refers to the annual diagnosis rate, or the number of new cases of Oral cancer diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

Footnotes: 1. SEER Cancer Statistics Review 1975-2000, National Cancer Institute (NCI)